Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emixustat in Proliferative Diabetic Retinopathy
NCT02753400Phase 2Completed
- Sponsor
- Kubota Vision
- Start
- May 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in proliferative diabetic retinopathy (PDR) comparing Emixustat hydrochloride with Placebo (2 arms). Primary endpoint: Change in Aqueous Humor Concentration of Biomarkers at 12 weeks. Started May 2016; status: completed.
02
Drugs
emixustat
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT02753400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753400.